A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Titre officiel

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Sommaire:

Cette étude vise à déterminer si le nouveau médicament PX-866 permettra de ralentir la progression du cancer de la prostate. Les chercheurs surveilleront également les effets secondaires que le PX-866 pourrait entraîner.

Description de l'essai

Primary Outcome:

• Efficacy

Secondary Outcome:

• Tolerability and toxicity of PX-866 in this population
• PSA response; Objective response and change in circulating tumour cell number
• Access if PX-866 inhibits a molecule related to cancer cell growth
• Access effect of PX-866 on platelets

PX 866 is a new type of drug that inhibits a molecule related to cancer cell growth. While this molecule is also found in normal cells, it is much more active in some cancer cells, so inhibiting the molecule with PX-866 is hoped to slow the growth of cancer cells. Laboratory tests show that it may help slow the growth of prostate cancer in animals, but it is not known whether it will have the same effects in humans. PX-866 has been studied in some cancer patients to find out safe doses that can be given but it has not undergone study in prostate cancer. This study will be the first study of PX-866 in prostate cancer. Health Canada has not approved the sale or use of PX-866 to treat prostate cancer, although they have approved its use in this clinical trial.

Voir cet essai sur ClinicalTrials.gov